Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
The partnership aims to co-develop full-stack AI infrastructure, targeting enterprise and industrial use cases in Japan and beyond.
The ISM Services PMI unexpectedly fell to the breakeven point of 50, missing market forecasts and raising new questions about US economic momentum.
ProSense cryoablation system gains marketing authorization as the first minimally invasive treatment for low-risk tumors in women over 70.
Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.